GSK Press Release

[idpickering]

I guess most of us here hold GlaxoSmithKline, as do I, so this might prove of interest here.

ViiV Phase III results Dolutegravir & Rilpivirine

"In the SWORD studies, the two-drug regimen showed comparable efficacy to three- or four-drug regimens in virologically suppressed patients."

Full item here;

http://www.investegate.co.uk/glaxosmith ... 00057793W/

[77ss]

I guess most of us here hold GlaxoSmithKline, as do I, so this might prove of interest here.

ViiV Phase III results Dolutegravir & Rilpivirine

"In the SWORD studies, the two-drug regimen showed comparable efficacy to three- or four-drug regimens in virologically suppressed patients."

Full item here;

http://www.investegate.co.uk/glaxosmith ... 00057793W/

Thus seems to have been going on forever! The bit that caught my eye:

We are planning regulatory submissions for this two-drug regimen as a single tablet in 2017.